Source comparison
Does Tesamorelin + Ipamorelin Blend Help Visceral Fat Research? Comparison
Tesamorelin monotherapy (MGH, 2020) 15.2% 26 weeks MRI (L4–L5) +41% above baseline Plateau after week 20; no further reduction at 52 weeks Ipamorelin monotherapy (preclinical rodent) 8.1% 8 weeks Micro-CT +18% above baseline Minimal effect on trunk fat; subcut
This comparison does not assign a generated winner or score.
- Tesamorelin monotherapy (MGH, 2020)
- 15.2%
- 26 weeks
- MRI (L4–L5)
- +41% above baseline
- Plateau after week 20; no further reduction at 52 weeks
- Ipamorelin monotherapy (preclinical rodent)
- 8.1%
- 8 weeks
- Micro-CT
- +18% above baseline
- Minimal effect on trunk fat; subcutaneous loss predominates
- Tesamorelin + ipamorelin blend (Miami, 2022)
- 18.1%
- 24 weeks
- +38% above baseline
- Small sample size (n=48); single-site study
- Caloric restriction + exercise (meta-analysis)
- 4.7%
- CT or MRI
- No change
- VAT loss proportional to total weight loss; no compartment specificity
- GH replacement therapy (clinical endocrinology)
- 11.3%
- 52 weeks
- DEXA + MRI
- +89% above baseline
- High side-effect burden; joint pain in 34% of participants
- Professional Assessment
- Tesamorelin + ipamorelin blend produces the highest sustained VAT reduction with moderate IGF-1 elevation. Avoiding the plateau seen in monotherapy and the side-effect profile of direct GH administration. For visceral fat-specific research, it remains the most targeted pharmacological model available.